Literature DB >> 20723572

Urotensin II alters vascular reactivity in animals subjected to volume overload.

Gregory S Harris1, Robert M Lust, Laxmansa C Katwa, Christopher J Wingard.   

Abstract

Congestive heart failure (CHF) alters vascular reactivity and up regulates in urotensin II (UTII), a potent vasoactive peptide. The aim of this study was to investigate the interaction between CHF and UTII in altering vascular reactivity in a rat model of volume overload heart failure. Animals were divided into 4 groups: control, UTII infused (UTII), volume overload only (VO) or volume overload+UTII (VO+UTII). Volume overload was established by the formation of an aortocaval fistula. Following fistula formation animals were administered UTII at a rate of 300 pmol/kg/h for 4 weeks subcutaneously with mini-osmotic pumps. Thoracic aorta rings, with/without endothelium, were subjected to cumulative dose-responses to phenylephrine, sodium nitroprusside (SNP), acetylcholine (ACH), UTII, and the Rho-kinase inhibitor HA-1077. Aortas from VO animals exhibited increased sensitivity to phenylephrine and UTII with a decreased relaxation response to ACH and HA-1077. Aortas from animals subjected to chronic UTII with volume overload (VO + UTII) retained their sensitivity to phenylephrine and UTII while they improved their relaxation to HA-1077 but not ACH. The constrictive response to UTII was dose-dependent and augmented at concentrations <0.01 μM in VO animals. The changes in vascular reactivity paralleled an elevation of both the UTII and α(1A)-adrenergic receptor while the Rho and Rho-kinase signalling proteins were diminished. We found that volume overload increased sensitivity to the vasoconstrictor agents that was inversely related to changes in the Rho-kinase expression. The addition of UTII with VO reversed the constrictive vascular response through alterations in the Rho-kinase signalling pathway.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20723572      PMCID: PMC2953595          DOI: 10.1016/j.peptides.2010.07.023

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  50 in total

1.  Plasma urotensin in human systolic heart failure.

Authors:  Leong L Ng; Ian Loke; Russell J O'Brien; Iain B Squire; Joan E Davies
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

Authors:  Wojciech J Rossowski; Beng-L Cheng; John E Taylor; Rakesh Datta; David H Coy
Journal:  Eur J Pharmacol       Date:  2002-03-08       Impact factor: 4.432

Review 3.  Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

Authors:  Stephen A Douglas
Journal:  Curr Opin Pharmacol       Date:  2003-04       Impact factor: 5.547

Review 4.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase.

Authors:  V Sauzeau; E Le Mellionnec; J Bertoglio; E Scalbert; P Pacaud; G Loirand
Journal:  Circ Res       Date:  2001-06-08       Impact factor: 17.367

6.  Plasma urotensin II in heart failure.

Authors:  A Mark Richards; M Gary Nicholls; John G Lainchbury; Stephen Fisher; Timothy G Yandle
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

7.  Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat.

Authors:  Xi Wang; Bin Ren; Songyan Liu; Emmanuelle Sentex; Paramjit S Tappia; Naranjan S Dhalla
Journal:  J Appl Physiol (1985)       Date:  2003-02

8.  Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts.

Authors:  Naohiko Kobayashi; Shigeo Horinaka; Shin-ichiro Mita; Shigefumi Nakano; Takeaki Honda; Kohtaro Yoshida; Tsutomu Kobayashi; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2002-09       Impact factor: 10.787

9.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  Congestive heart failure and expression of myocardial urotensin II.

Authors:  Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.